• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受慢性羟氯喹治疗的患者中的 COVID-19 肺炎：三例 COVID-19 肺炎病例

COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia.

作者信息

Rahman Awan K, Purdy Adam G, Ender Peter T

机构信息

Section of Pulmonary and Critical Care, St. Luke's University Health Network, Bethlehem, PA, USA.

Section of Infectious Diseases, St. Luke's University Health Network, Bethlehem, PA, USA.

出版信息

Case Rep Infect Dis. 2020 Oct 22;2020:8822753. doi: 10.1155/2020/8822753. eCollection 2020.

DOI:10.1155/2020/8822753
PMID:33123391
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7582078/
Abstract

Hydroxychloroquine has gained popularity as a potential preventative and treatment of COVID-19 pneumonia due to its in vitro activity against the virus. These three cases of COVID-19 pneumonia of varying severities occurred in the setting of chronic hydroxychloroquine use. These cases argue against the use of hydroxychloroquine as a preventative or therapeutic option for COVID-19 pneumonia.

摘要

由于羟氯喹对新冠病毒的体外活性，它作为新冠病毒肺炎的潜在预防和治疗药物受到了关注。这三例不同严重程度的新冠病毒肺炎发生在长期使用羟氯喹的情况下。这些病例表明不支持将羟氯喹作为新冠病毒肺炎的预防或治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47aa/7582078/a2163582ab9c/CRIID2020-8822753.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47aa/7582078/8f7e6c4cc895/CRIID2020-8822753.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47aa/7582078/eec94b1b24af/CRIID2020-8822753.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47aa/7582078/a2163582ab9c/CRIID2020-8822753.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47aa/7582078/8f7e6c4cc895/CRIID2020-8822753.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47aa/7582078/eec94b1b24af/CRIID2020-8822753.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47aa/7582078/a2163582ab9c/CRIID2020-8822753.003.jpg

相似文献

1
COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia.接受慢性羟氯喹治疗的患者中的 COVID-19 肺炎：三例 COVID-19 肺炎病例
Case Rep Infect Dis. 2020 Oct 22;2020:8822753. doi: 10.1155/2020/8822753. eCollection 2020.
2
When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?当大流行发生时，没有时间可以浪费：我们的应对新冠肺炎感染患者的手段中应该有羟氯喹吗？
Mediterr J Rheumatol. 2020 Mar 31;31(1):94-97. doi: 10.31138/mjr.31.1.94. eCollection 2020 Mar.
3
Acute Respiratory Failure Secondary to COVID-19 Viral Pneumonia Managed With Hydroxychloroquine/Azithromycin Treatment.新冠病毒肺炎继发急性呼吸衰竭采用羟氯喹/阿奇霉素治疗
Cureus. 2020 May 25;12(5):e8268. doi: 10.7759/cureus.8268.
4
Hydroxychloroquine-Associated Hypoglycemia in Hemodialysis Patients With COVID-19.新型冠状病毒肺炎血液透析患者中与羟氯喹相关的低血糖症
Kidney Int Rep. 2020 Oct;5(10):1811-1814. doi: 10.1016/j.ekir.2020.06.039. Epub 2020 Jul 12.
5
Hydroxychloroquine in a COVID-19 patient on chronic Pregabalin therapy- Is it safe?正在接受普瑞巴林长期治疗的新冠肺炎患者使用羟氯喹是否安全？
J Anaesthesiol Clin Pharmacol. 2022 Jul;38(Suppl 1):S127-S128. doi: 10.4103/joacp.JOACP_587_20. Epub 2022 Jan 7.
6
Correction: Hydroxychloroquine as a Preventive and Therapeutic Option in Preeclampsia - a Literature Review.更正：羟氯喹作为子痫前期的预防和治疗选择——文献综述。
Geburtshilfe Frauenheilkd. 2020 Jul;80(7):e71. doi: 10.1055/a-1230-0002. Epub 2020 Aug 11.
7
A real-world study of glucocorticoid treatment in COVID-19 patients with different disease severities.一项针对不同疾病严重程度的新冠肺炎患者糖皮质激素治疗的真实世界研究。
Clin Transl Med. 2020 Dec;10(8):e235. doi: 10.1002/ctm2.235.

引用本文的文献

1
Fractal-fractional order mathematical vaccine model of COVID-19 under non-singular kernel.非奇异核下COVID-19的分形-分数阶数学疫苗模型
Chaos Solitons Fractals. 2021 Sep;150:111150. doi: 10.1016/j.chaos.2021.111150. Epub 2021 Jun 12.
2
Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.新型冠状病毒肺炎的临床管理：药理学治疗选择综述
Pharmaceuticals (Basel). 2021 May 28;14(6):520. doi: 10.3390/ph14060520.

本文引用的文献

1
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
2
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
3
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
羟氯喹治疗中度新型冠状病毒肺炎患者的一项试点研究
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
4
Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.氯喹和羟氯喹在 COVID-19 和其他病毒感染中的治疗用途：叙述性综述。
Travel Med Infect Dis. 2020 May-Jun;35:101735. doi: 10.1016/j.tmaid.2020.101735. Epub 2020 May 6.
5
Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility.在一家专业护理机构中出现的 SARS-CoV-2 感染前驱期和传播。
N Engl J Med. 2020 May 28;382(22):2081-2090. doi: 10.1056/NEJMoa2008457. Epub 2020 Apr 24.
6
2019 Novel coronavirus (COVID-19) overview.2019新型冠状病毒（COVID-19）概述。
Z Gesundh Wiss. 2022;30(1):167-175. doi: 10.1007/s10389-020-01258-3. Epub 2020 Apr 19.
7
SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment.系统性红斑狼疮、羟氯喹与非系统性红斑狼疮的新冠肺炎患者：一则评论
Ann Rheum Dis. 2020 Jun;79(6):e61. doi: 10.1136/annrheumdis-2020-217506. Epub 2020 Apr 15.
8
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.羟氯喹和阿奇霉素联合治疗至少随访 6 天的 80 例 COVID-19 患者的临床和微生物学效果：一项前瞻性观察研究。
Travel Med Infect Dis. 2020 Mar-Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.
9
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
10
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.